NICE

NICE set to reject wider use of Eisai’ s breast cancer drug Halaven. ... NICE agreed last year that Halaven should be made available on the NHS as a third-line option after two prior rounds of chemotherapy.

MHRA joins Instagram as part of Yellow Card drive. UK medicines regulator follows in the footsteps of NICE in using the channel. ... month. NICE has focused on AMR and diabetes to date, while the UK medicines regulator has so far using Instgram to

NICE backs two advanced breast cancer drugs after price cuts. An estimated 8, 000 women will be eligible to receive the drugs due to discounts. ... in others, ”commented Prof Carole Longson, director of the centre for health technology evaluation at

NICE and pharma. Also high on the agenda at the event was NICE’s approach to appraising new medicines. ... The NHS is interested in managing access, not in blocking it, ”he said, adding that NICE and pharma were “in the same business”.

Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

Yet often the insights about patients can still be considered ‘nice to have’rather than a ‘must have’. ... It may undermine the clinician’s nice, linear view of the journey and present a more convoluted, less logical route.

In April 2017, NICE and NHS England introduced affordability measures to manage the uptake of innovative treatments, including a £20m budget impact threshold for all new medicines. ... The ABPI has pursued legal action, arguing that this contravenes the

Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around

Former NICE chair Sir Michael Rawlins to lead MHRA. He will take up his new role at the UK's medicines and devices regulator in December. ... Care Excellence (NICE) from its formation in 1999 to his departure last year.

Medical authorities including the British Gastroenterology Society and the British Society for Rheumatology have accepted the evidence that biosimilars perform as well as the originator drugs, and NICE now recommends the

The CCGs will be monitored by four Regional Medicines Optimisation Committees(RMOCs) which were launched recently to avoid duplication when evaluating medicines, particularly those which are not evaluated by NICE.